HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Fanotto, Valentina, Ongaro, Elena, Rihawi, Karim, Avallone, Antonio, Silvestris, Nicola, Fornaro, Lorenzo, Vasile, Enrico, Antonuzzo, Lorenzo, Leone, Francesco, Rosati, Gerardo, Giuliani, Francesco, Bordonaro, Roberto, Scartozzi, Mario, Maglio, Giovanna De, Negri, Francesca V., Fasola, Gianpiero, Aprile, Giuseppe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356612/
https://ncbi.nlm.nih.gov/pubmed/27542243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11264
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg